Showing 8 of 8 recruiting trials for “PIK3CA-related overgrowth syndrome”
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Use of Airpod Pros as Assistive Technology
👨⚕️ Linda Thibodeau, Ph.D., The University of Texas at Dallas📍 1 site📅 Started Jul 2025View details ↗
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
RecruitingNCT06956248 ↗
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
👨⚕️ Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD, National Cancer Centre, Singapore📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06364579 ↗
Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
👨⚕️ Stefania Manfrida, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Mar 2024View details ↗
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
RecruitingNCT05898932 ↗
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →